Cambiar Investors LLC Has $4.77 Million Holdings in Waters Corporation $WAT

Cambiar Investors LLC decreased its holdings in shares of Waters Corporation (NYSE:WAT) by 33.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 15,905 shares of the medical instruments supplier’s stock after selling 7,856 shares during the quarter. Cambiar Investors LLC’s holdings in Waters were worth $4,768,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of WAT. Vanguard Group Inc. boosted its stake in Waters by 1.9% in the second quarter. Vanguard Group Inc. now owns 7,410,763 shares of the medical instruments supplier’s stock valued at $2,586,653,000 after acquiring an additional 138,511 shares during the last quarter. Alliancebernstein L.P. lifted its stake in shares of Waters by 31.0% in the 2nd quarter. Alliancebernstein L.P. now owns 4,021,358 shares of the medical instruments supplier’s stock valued at $1,403,615,000 after purchasing an additional 950,687 shares during the period. Massachusetts Financial Services Co. MA boosted its position in shares of Waters by 44.3% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 2,689,693 shares of the medical instruments supplier’s stock worth $806,397,000 after purchasing an additional 825,723 shares during the last quarter. State Street Corp grew its stake in shares of Waters by 1.4% during the second quarter. State Street Corp now owns 2,676,198 shares of the medical instruments supplier’s stock worth $934,100,000 after purchasing an additional 37,763 shares during the period. Finally, Geode Capital Management LLC increased its holdings in Waters by 2.8% in the second quarter. Geode Capital Management LLC now owns 1,552,399 shares of the medical instruments supplier’s stock valued at $539,606,000 after purchasing an additional 42,202 shares during the last quarter. 94.01% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities analysts have recently issued reports on WAT shares. Rothschild Redb upgraded Waters to a “strong-buy” rating in a research report on Wednesday, October 8th. William Blair initiated coverage on shares of Waters in a report on Monday, January 5th. They set an “outperform” rating for the company. JPMorgan Chase & Co. upped their target price on shares of Waters from $300.00 to $325.00 and gave the company a “neutral” rating in a research note on Thursday, October 9th. Weiss Ratings reissued a “hold (c)” rating on shares of Waters in a research report on Wednesday, January 21st. Finally, Morgan Stanley assumed coverage on shares of Waters in a research report on Monday, December 1st. They issued an “equal weight” rating and a $423.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and nine have given a Hold rating to the company’s stock. According to data from MarketBeat, Waters has an average rating of “Moderate Buy” and a consensus price target of $398.61.

Waters Stock Down 0.3%

Shares of WAT stock opened at $389.62 on Wednesday. The firm’s fifty day moving average price is $390.82 and its two-hundred day moving average price is $342.40. The company has a current ratio of 1.53, a quick ratio of 1.08 and a debt-to-equity ratio of 0.41. Waters Corporation has a 1 year low of $275.05 and a 1 year high of $423.56. The firm has a market capitalization of $23.20 billion, a P/E ratio of 35.81, a PEG ratio of 3.27 and a beta of 1.16.

Waters (NYSE:WAT) last announced its quarterly earnings data on Tuesday, November 4th. The medical instruments supplier reported $3.40 earnings per share for the quarter, beating the consensus estimate of $3.21 by $0.19. The company had revenue of $799.89 million during the quarter, compared to analysts’ expectations of $780.05 million. Waters had a return on equity of 36.59% and a net margin of 20.89%.Waters’s revenue for the quarter was up 8.1% compared to the same quarter last year. During the same quarter last year, the company earned $2.93 EPS. Waters has set its FY 2025 guidance at 13.050-13.150 EPS and its Q4 2025 guidance at 4.450-4.550 EPS. On average, equities analysts predict that Waters Corporation will post 12.86 EPS for the current fiscal year.

Waters Company Profile

Waters Corporation is a global provider of analytical instruments, software and services for laboratory and research applications. The company designs, manufactures and sells technologies centered on liquid chromatography, mass spectrometry, separation science, and related sample preparation and detection systems. Its product portfolio includes chromatographs, mass spectrometers, columns and consumables, laboratory informatics and workflow software, as well as technical support and training services that help customers run and interpret complex analyses.

Waters serves a wide range of end markets that include pharmaceutical and biotechnology companies, contract research and testing laboratories, academic and government research institutions, clinical diagnostics, food and environmental testing, and industrial and chemical manufacturers.